within Pharmacolibrary.Drugs.ATC.G;

model G02CA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 3.1666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 900,            
    Vdp             = 0.0028,
    k12             = 4.6,
    k21             = 4.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fenoterol is a selective β2-adrenergic agonist used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is primarily administered by inhalation to relieve bronchospasm. Fenoterol was widely used in the past; however, due to concerns over increased risk of severe asthma exacerbations, its inhaled formulations have been withdrawn or restricted in many countries and it is less commonly used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Advenier, C, et al., &amp; Duroux, P (1984). [Bronchodilators]. <i>La semaine des hopitaux : organe fonde par l&#x27;Association d&#x27;enseignement medical des hopitaux de Paris</i> 60(3) 179–193. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6320443/\">https://pubmed.ncbi.nlm.nih.gov/6320443</a></p></li><li><p>Svedmyr, N (1985). Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. <i>Pharmacotherapy</i> 5(3) 109–126. DOI:<a href=\"https://doi.org/10.1002/j.1875-9114.1985.tb03409.x\">10.1002/j.1875-9114.1985.tb03409.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2991865/\">https://pubmed.ncbi.nlm.nih.gov/2991865</a></p></li><li><p>Hochhaus, G, &amp; Möllmann, H (1992). Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 30(9) 342–362. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1358833/\">https://pubmed.ncbi.nlm.nih.gov/1358833</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CA03;
